BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1251 related articles for article (PubMed ID: 18313757)

  • 1. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold.
    Desiderio A; Franconi R; Lopez M; Villani ME; Viti F; Chiaraluce R; Consalvi V; Neri D; Benvenuto E
    J Mol Biol; 2001 Jul; 310(3):603-15. PubMed ID: 11439027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity.
    Lee SH; Park DW; Sung ES; Park HR; Kim JK; Kim YS
    Mol Immunol; 2010 Jan; 47(4):816-24. PubMed ID: 19864027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
    Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
    Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.
    Kügler M; Stein C; Schwenkert M; Saul D; Vockentanz L; Huber T; Wetzel SK; Scholz O; Plückthun A; Honegger A; Fey GH
    Protein Eng Des Sel; 2009 Mar; 22(3):135-47. PubMed ID: 19188138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanization of high affinity anti-HBs antibody by using human consensus sequence and modification of selected minimal positional template and packing residues.
    Tiwari A; Khanna N; Acharya SK; Sinha S
    Vaccine; 2009 Apr; 27(17):2356-66. PubMed ID: 19428851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and dynamics of the anti-AMCV scFv(F8): effects of selected mutations on the antigen combining site.
    Arcangeli C; Cantale C; Galeffi P; Rosato V
    J Struct Biol; 2008 Oct; 164(1):119-33. PubMed ID: 18662789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the anti-His tag antibody 3D5 single-chain fragment complexed to its antigen.
    Kaufmann M; Lindner P; Honegger A; Blank K; Tschopp M; Capitani G; Plückthun A; Grütter MG
    J Mol Biol; 2002 Apr; 318(1):135-47. PubMed ID: 12054774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
    Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
    J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a stable recombinant antibodies repertoire for the direct selection of functional intracellular reagents.
    Villani ME; Di Carli M; Donini M; Traversini G; Lico C; Franconi R; Benvenuto E; Desiderio A
    J Immunol Methods; 2008 Jan; 329(1-2):11-20. PubMed ID: 17980894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermodynamics and kinetics of the reaction of a single-chain antibody fragment (scFv) with the leucine zipper domain of transcription factor GCN4.
    Weber-Bornhauser S; Eggenberger J; Jelesarov I; Bernard A; Berger C; Bosshard HR
    Biochemistry; 1998 Sep; 37(37):13011-20. PubMed ID: 9737882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
    Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
    Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
    Wang X; Campoli M; Ko E; Luo W; Ferrone S
    J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
    Wang Y; Li X; Chen W
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection, characterization and x-ray structure of anti-ampicillin single-chain Fv fragments from phage-displayed murine antibody libraries.
    Burmester J; Spinelli S; Pugliese L; Krebber A; Honegger A; Jung S; Schimmele B; Cambillau C; Plückthun A
    J Mol Biol; 2001 Jun; 309(3):671-85. PubMed ID: 11397088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
    Schlapschy M; Gruber H; Gresch O; Schäfer C; Renner C; Pfreundschuh M; Skerra A
    Protein Eng Des Sel; 2004 Dec; 17(12):847-60. PubMed ID: 15708864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
    Albrecht H; Denardo GL; Denardo SJ
    J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
    Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD
    J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.